Targovax ASA: Fourth quarter and full year 2018 results
Oslo, Norway, 14 February 2019 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter and full year 2018 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below). HIGHLIGHTS FOR THE FOURTH QUARTER 2018 · In October, the Company reported the full data set from the TG01 trial in resected pancreatic cancer. The trial showed six months improvement in median overall survival (mOS) data over comparable historical